Immunologists seek ways to make TIL in solid tumors as effective as CAR T in blood cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

For more than four decades, Steven Rosenberg’s work on tumor infiltrating lymphocytes has met with equal measures of skepticism and cheer—but now, as more patients across multiple cancer types respond to cell transfer immunotherapy, researchers are eager to join the movement Rosenberg indisputably leads.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?
Matthew Bin Han Ong
Matthew Bin Han Ong

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.

Login